Substance Use in Pregnancy: What to Tell Patients
The Carlat Addiction Treatment Report, Volume 5, Number 8, November 2017
Cresta Wedel Jones, MD, FACOG
Maternal-fetal medicine physician and assistant professor at the University of Minnesota Medical School.
Dr. Jones has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In this article, I’ll start by briefly outlining what the research tells us about the risks of substance use to the fetus. The more informed you are about these risks, the more persuasive and helpful you can be to patients. I’ll then move on to discussing how, as an OB/GYN, I approach the evaluation and treatment of these patients, emphasizing issues of interest to clinicians.